Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Pre-Tax Margin
Income before tax as a percentage of revenue.
Century Therapeutics, Inc.NASDAQ: IPSC
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin not reported for Q1 FY2026
Over 3 fiscal years it widened by 2507.8 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -8.8%
- Year-over-year change
- +1884.9pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -8.8% | +1884.9pp |
| FY2024 | 2024-12-31 | -1893.7% | +4137.3pp |
| FY2023 | 2023-12-31 | -6031.0% | -3514.3pp |
| FY2022 | 2022-12-31 | -2516.7% | — |
| FY2021 | 2021-12-31 | — | — |
Pre-Tax Margin vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's FY2025 pre-tax margin of -8.8% is the highest of the 5 companies compared; the peer median is -519.9%.
- Its year-over-year change of +1884.9 pp is the 2nd highest of 5, against a peer median of +182.4 pp.
- Over three fiscal years its change of +2507.8 pp compares with a peer median of +2066.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | -8.8% | +1884.9 pp | +2507.8 pp | |
| LTM Mar 2026 | -58.1% | +449.8 pp | +4162.8 pp | |
| LTM Mar 2026 | -129.0% | -85.0 pp | -29.2 pp | |
| LTM Mar 2026 | -910.7% | +17056.9 pp | — | |
| LTM Mar 2026 | -18764.2% | -31180.7 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
OSTXOS Therapies Incorporated | FY2025 | — | — | — |
| Peer median (excluding IPSC) | -519.9% | +182.4 pp | +2066.8 pp | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 5.2M | 2.24M | 6.59M | 109.16M |
| Cost of Revenue | 4.58M | 0 | 0 | 0 | 13.1M |
| Gross Profit | (4.58M) | 5.2M | 2.24M | 6.59M | 96.06M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 88.0% |
| Research & Development | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M |
| Selling, General & Admin | 14.65M | 31.86M | 34.71M | 33.16M | 24M |
| Operating Expenses | 90.3M | 139.03M | 148.78M | 144.73M | 111.1M |
| Depreciation & Amortization | 4.58M | 8.44M | 13.04M | 13.3M | 13.1M |
| EBITDA | (89.92M) | (121.2M) | (121.21M) | (111.47M) | 3.45M |
| EBITDA Margin | — | -2331.2% | -5423.2% | -1691.8% | 3.2% |
| Operating Income | (94.88M) | (133.83M) | (146.55M) | (138.14M) | (15.04M) |
| Operating Margin | — | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Interest Income | 898K | 2.99M | 12.68M | 13.01M | 7.35M |
| Interest Expense | 1.28M | 0 | 540K | 0 | 0 |
| Other Income / Expenses | (898K) | 2.99M | 11.75M | 13.36M | 5.39M |
| Income Before Tax | (95.78M) | (130.84M) | (134.79M) | (124.78M) | (9.65M) |
| Pre-Tax Margin | — | -2516.7% | -6031.0% | -1893.7% | -8.8% |
| Income Tax Expense | 43K | 91K | 1.88M | 1.79M | (68K) |
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Net Margin | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (Basic) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| EPS (Diluted) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| Weighted Avg Shares | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
| Weighted Avg Shares (Diluted) | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.